male-dr

Leading the world in
early cancer detection research

Our innovative cancer screening
studies mean better outcomes for patients

female-dr

Innovation in cancer research
and development

We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics

female-dr

Non-invasive and affordable early
cancer screening and monitoring
solution

90% of cancers are curable if caught early
Your Health is Our Focus!

Early cancer detection research for a better future

BIOMARK’S MISSION

BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics, dynamic clinical data, radiomics and leveraging the power of machine learning.

WHAT IS A BIOMARKER?

According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:

  • proteins (e.g. an enzyme or receptor)
  • nucleic acids (e.g. a microRNA or other non-coding RNA)
  • antibodies
  • and peptides among other categories

A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.

POTENTIAL CLINICAL USES OF CANCER BIOMARKERS

Biomarkers have many potential applications in oncology including:

  • Estimating risk of cancer
  • Screening for occult primary cancers
  • Distinguishing benign from malignant findings or one type of malignancy from another
  • Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
  • Personalizing a treatment program especially for immunotherapy applications
  • Help in assessing pseudo progression with imaging modalities

VIDEOS: CANCER EDUCATION

LATEST POSTS

Alberta research to spot early stage lung cancer

6

Apr, 2021

Alberta research to spot early stage lung cancer

By: | Tags:

Mikenomics  | April 6, 2021 Earlier and faster cancer detection is the goal of research underway here in Alberta.​With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based at the University of Alberta is leading the new effort. Too often…

READ MORE
A simple blood test to detect lung cancer

31

Mar, 2021

A simple blood test to detect lung cancer

By: | Tags:

March 18, 2021 A new project funded by the Canadian Cancer Society (CCS) could transform how lung cancer is detected and help save lives.  Dr David Wishart  A new project funded by the Canadian Cancer Society (CCS) could transform how lung cancer is detected and help save lives. Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death in Canada. When lung cancer is detected…

READ MORE

NEWS RELEASES

BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC

April 29, 2021

Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment.   The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering […]


READ MORE

STOCK QUOTE

BIOMARK AWARDS, GRANTS, RECOGNITIONS

BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.

Read More